Skip to main content Skip to search Skip to main navigation

Swissmedic: Amendment to GMP Compliance by Foreign Manufacturers

Swissmedic has updated its guidance on Good Manufacturing Practice (GMP) compliance for foreign manufacturers, clarifying documentation requirements for various application types (e.g., new authorizations, type IA/IB/II changes for human and veterinary medicines).

To prove GMP compliance, documents must be provided by the Responsible Person (RP). Preferably, these should be certificates from authorities with GMP systems recognized as equivalent to Switzerland’s. If such certificates are unavailable, audit reports may be accepted under specific conditions.

Key Clarifications on Audit Reports:

  • The approved audit report should be submitted with the application. Manufacturer approval depends on this report.
  • Re-audit reports with reduced scope are accepted if missing details are addressed through an RP assessment or a RP summary based on the original complete audit covering the missing points.
  • Redacted documents (report/CAPA plan) are allowed if the assessment is not compromised.
  • Audit reports must be no older than three years and must cover the relevant product.

Inspection Reports:

Reports from recognized authorities are accepted if:

  • Not older than three years,
  • The inspection was conducted on-site, 
  • Relevant to the product in question.

Veterinary Medicines:

For notifications under Art. 39 VAZV, one copy of the GMP certificate or manufacturing authorization per foreign manufacturer is sufficient. If unavailable, an RP-prepared risk assessment may be submitted instead. Swissmedic provides guidance on the required content to ensure it proves GMP compliance.

The updated guidance took effect on 1 May 2025.


Source:

Swissmedic: General communications


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

How is a QRM process initiated?

How is a QRM process initiated?

You can view the answer here:
Read more
FDA: Updated Pre-RFD Guidance for Combination Products

FDA: Updated Pre-RFD Guidance for Combination Products

The U.S. FDA has released an updated final guidance on preparing a Pre-Request for Designation (Pre-RFD), replacing the previous 2018 version. The revised document provides new recommendations for interacting with the Office of Combination Products (OCP) and clarifies expectations for Pre-RFD submissions.
Read more
EDQM: 9 Virtual Training Modules on Ph. Eur. and CEPs

EDQM: 9 Virtual Training Modules on Ph. Eur. and CEPs

The EDQM has introduced a modular training programme covering chemically defined active substances and medicinal products. It will take place between 1 and 12 December 2025.
Read more
 Data Integrity and Data Governance

Data Integrity and Data Governance

Data integrity is a key element in the pharmaceutical quality assurance system which has gained importance in recent years, especially from the viewpoint of the authorities. In GxP-regulated companies, managers are responsible for identifying and minimising risks to data integrity (“data governance”).

Read more
EMA Clarifies “Novel or Complex Manufacturing Process” Definition

EMA Clarifies “Novel or Complex Manufacturing Process” Definition

In its Quality of Medicines Q&A – Part 1, the EMA has clarified how “novel or complex manufacturing processes” should be interpreted for variation categories Q.II.b.1 (new/replacement finished product manufacturing site) and Q.II.b.4 (change in batch size).
Read more
EU: Environment Committee Comments on EU Regulation Regarding Critical Medicines

EU: Environment Committee Comments on EU Regulation Regarding Critical Medicines

The Environment Committee of the European Parliament has issued its opinion on the proposed EU Regulation to strengthen the availability of critical medicines. Key recommendations include fast-track permitting, simplified environmental assessments, and support for strategic manufacturing projects to boost EU production capacity.
Read more
Previous
Next